PURPOSE There is a shortage of radiation therapy service centers in low- to middle-income countries. TARGIT–intraoperative radiation therapy (IORT) may offer a viable alternative to improve radiation treatment efficiency and alleviate hospital patient loads. The Breast Care Unit in Johannesburg became the first facility in Africa to offer TARGIT-IORT, and the purpose of this study was to present a retrospective review of patients receiving IORT at this center between November 2017 and May 2020.

PATIENTS AND METHODS Patient selection criteria were based mainly on the latest American Society of Radiation Oncology guidelines. Selection criteria included early-stage breast carcinoma (luminal A) and luminal B with negative upfront sentinel lymph node biopsy that negated external-beam radiation therapy (EBRT). Patient characteristics, reasons for choosing IORT, histology, and use of oncoplastic surgery that resulted in complications were recorded.

RESULTS One hundred seven patients successfully received IORT/TARGIT-IORT. Mean age was 60.8 years (standard deviation, 9.3 years). A total of 73.8% of patients presented with luminal A, 15.0% with luminal B, and 5.6% with triple-negative cancer. One patient who presented with locally advanced breast cancer (T4N2) opted for IORT as a boost in addition to planned EBRT. Eighty-seven patients underwent wide local excision (WLE) with mastopexy, and 12 underwent WLE with parenchymal. Primary reasons for selecting IORT/TARGIT-IORT were distance from the hospital (43.9%), choice (40.2%), and age (10.3%).

CONCLUSION This retrospective study of IORT/TARGIT-IORT performed in Africa confirms its viability, with low complication rates and no detrimental effects with breast conservation, resulting in positive acceptance and the potential to reduce Oncology Center patient loads. Limitations of the study include the fact that only short-term data on local recurrence were available. Health and socioeconomic value models must still be addressed in the African setting.

INTRODUCTION Breast cancer is one of the most common types of cancers affecting women, second to skin cancer, with a 100 times greater prevalence rate in women than in men. Early detection of breast cancer, coupled with radiation treatment, can dramatically reduce mortality rates and reduce the need for mastectomies. Alternatives to a mastectomy are breast conservation surgery (BCS) followed by a 6- or 7-week course of external-beam radiation therapy (EBRT). The postoperative radiation therapy (RT) regimen, if not completed, adversely affects the efficacy of treatment and increases the need for a mastectomy. Delivering a single fraction using TARGIT–intraoperative radiation therapy (IORT) in theater after surgery reduces the need for postsurgical treatment, reduces the impact on the patient’s lifestyle, and reduces cost. Although numerous studies detail the efficacy of IORT in early-stage breast carcinomas, limited information is available characterizing the post-treatment affects or detailing any nuances within the Southern Africa patient context. Traditional long-term studies deal primarily with recurrence rate, survival tests, and efficacy comparisons with EBRT. TARGIT-IORT has been largely adopted in developed countries, with protocols based on these countries; however, there is a paucity of data of value in middle- and lower-income countries such as South Africa. Exacerbating this problem was the complete absence of operational TARGIT-IORT equipment in Africa before November 2017.

The emergence of a disease presenting with primary acute viral respiratory tract infection and other severe
symptoms, which emanated from Wuhan, China, in late 2019, named COVID-19 and caused by SARS-CoV-2 infection, has resulted in a global epidemic spreading across all habitable regions.\(^5\),\(^6\) This has resulted in the implementation of extreme procedural measures to limit viral transmission in hospitals. However, improved cleaning procedures have led to reduced operating capacity in oncologic centers.\(^7\),\(^8\) Factors negatively affecting radiation treatment adherence include the requirement for COVID-19 tests before treatment, a lack of COVID-19 testing kits, the length of time it takes to receive COVID-19 test results, social distancing measures, and forced isolation.

The purpose of this study was to characterize patient demographics; record multifactorial post-treatment effects such as complications, both local and those related to cardiac response; and identify early and late toxicities in adult females diagnosed with early-stage breast carcinoma who presented between November 2017 and May 2020. Patients presented primarily from the Southern African region.

Before considering TARGIT-IORT for a patient presenting with early-stage breast cancer (typically, luminal A type) detected by imaging or examination, a confirmation sentinel lymph node biopsy was performed to confirm negative lymph nodes together with other relevant factors. Patients were discussed in a multidisciplinary meeting before being assessed by specialist surgeons and radiation oncologists, who discussed applicable treatments, including advantages, disadvantages, and funding; if TARGIT-IORT was selected, informed consent was obtained. Patients choosing alternative therapies were referred to appropriate treatment facilities.

Inclusion criteria, which were more restrictive than those in the TARGIT-A trial, included patients presenting between November 2017 and May 2020 who had medical records available for review and those mainly meeting American Society of Radiation Oncology (ASTRO) guidelines.\(^10\) Notably, patients who were included were those who were older than 50 years and who met the following criteria: invasive ductal carcinoma, tumor stage T1/T2, and tumor size \(<\) 3.5 cm; ductal carcinoma in situ (DCIS) was included if it was low to intermediate grade and \(<\) 2.5 cm, with resection margins \(>\) 1 cm.\(^10\) Exclusions included bilateral breast cancer at the time of diagnosis. However, any severe concomitant disease that may have limited life expectancy or a history of malignant disease did not preclude entry if the expectation of relapse-free survival at 10 years was 90% or greater.

The majority of patients selected for TARGIT-IORT presented with early-stage disease and had a negative upfront sentinel lymph node biopsy, negating the need for EBRT. Patient characteristics, histology, the use of oncoplastic surgery, and any early complications were recorded.

BCS with sentinel node harvesting was took place, after which TARGIT-IORT was performed using the Intrabeam
system (50 kVp, Carl Zeiss Surgical, Oberkochen, Germany), as presented in Figure 1. After lumpectomy, spherical treatment applicators, 5, 4.5, 4, and 3.5 cm in size, used routinely, as shown in Figure 2, were attached to the probe-like end of the unit, surgically inserted in the tumor bed, and closed via a purse-string suture, ensuring close apposition to the target tissues and reducing stray radiation to unintended tissue.

Before each clinical case, the output of the Intrabeam mini-accelerator x-ray source (XRS) was measured using a PTW 23342 ionization chamber (IC) together with the probe adjuster/IC holder quality assurance device. The measured exposure was converted to absorbed dose to water using a factor of $f = 0.881$ cGy/Roentgen. Typically, a 20-Gy radiation dose at 0 mm depth is delivered to the tumor bed, with treatment times in the range of 16 to 50 min determined using the manufacturer’s calibration depth-dose curves. Iso-dose curves were verified using a special water phantom device provided by the manufacturer with a PTW-34013 soft chamber. This allowed the XRS to be mounted superiorly on the top of the phantom device with the probe intercepting the water bath; this probe could be adjusted incrementally in any three-dimensional $(x, y, z)$ direction.

**RESULTS**

One hundred seven patients were selected to undergo TARGIT-IORT during lumpectomy at the Breast Care Center between November 2017 and May 2020, with an average 2-year follow-up period per patient.

The mean age was 60.8 years (standard deviation, 9.3 years), and all patients were female. The patient and tumor characteristics are listed in Table 1. Coincidental tumors were not reported. No telangiectasia was noted for any patients in this study.

**Adoption of IORT/TARGIT-IORT and After Treatment**

Before administering the TARGIT-IORT treatment regimen, distance (43.9%) and choice (40.2%) were reported as the patients’ indication and primary reasons for opting to undergo TARGIT-IORT (Table 2). Patients were more willing to choose IORT/TARGIT-IORT because of delayed treatment times at EBRT machines, potential contact at hospital treating facilities, and general unease during the COVID-19 period. A recurrence rate of 1.9% (two of 107) was reported. A complication rate of 2.8% (three of 107), defined as major complications (fat necrosis and/or skin erythema), was reported.
**TABLE 1. Preoperative Patient and Tumor Characteristics**

| Characteristic          | Value          |
|-------------------------|----------------|
| Age, years              | Mean (SD) 60.8 (9.3) |
|                         | Median (range) 60 (43-86) |
| **Side**                |                |
| Right                   | 45 (42.1)      |
| Left                    | 62 (57.9)      |
| **Grade**               |                |
| 1                       | 57 (53.3)      |
| 2                       | 28 (26.2)      |
| 2 and 1                 | 1 (0.9)        |
| 3                       | 9 (8.4)        |
| HG                      | 4 (3.7)        |
| IG                      | 3 (2.8)        |
| LG                      | 5 (4.7)        |
| **Histology**           |                |
| DCIS                    | 1 (0.9)        |
| DUCT                    | 67 (62.6)      |
| DUCT NST                | 1 (0.9)        |
| HG DCIS                 | 3 (2.8)        |
| IDC                     | 8 (7.5)        |
| IG DCIS                 | 3 (2.8)        |
| L tubular               | 1 (0.9)        |
| LG DCIS                 | 5 (4.7)        |
| Lobular                 | 14 (13.1)      |
| Pleomorphic lobular     | 1 (0.9)        |
| Tubular                 | 3 (2.8)        |
| **Tumor size, mm**      |                |
| Mean (SD)               | 15.2 (11.5)    |
| Median (range)          | 11 (1.2-59)    |
| **TMN classification, mm** |            |
| T1, tumor ≤ 20          | 71 (66.4)      |
| T2, tumor > 20 but ≤ 50 | 22 (20.6)      |
| T3, tumor > 50          | 0 (0)          |
| T4, tumor of any size with direct extension to the chest wall and/or to the skin | 1 (0.9) |
| Tis, DCIS               | 13 (12.1)      |
| **ER**                  |                |
| Positive                | 99 (92.5)      |
| Negative                | 8 (7.5)        |
| Not recorded            | 0 (0)          |
| **PR**, %               |                |
| Positive                | 89 (83.2)      |
| Negative                | 15 (14.0)      |
| Not recorded            | 3 (2.8)        |

(Continued in next column)

**TABLE 1. Preoperative Patient and Tumor Characteristics (Continued)**

| Characteristic          | Value          |
|-------------------------|----------------|
| HER2                    |                |
| Negative                | 105 (98.1)     |
| Positive                | 2 (1.9)        |
| **KI 67**, %            |                |
| ≥ 14                    | 26 (24.3)      |
| < 14                    | 75 (70.1)      |
| Not recorded            | 6 (5.6)        |
| **Molecular subtype**   |                |
| A                       | 79 (73.8)      |
| B                       | 16 (15.0)      |
| DCIS                    | 6 (5.6)        |
| TN                      | 6 (5.6)        |
| **Surgery**             |                |
| WLE and mastopexy       | 87 (81.3)      |
| WLE and parenchymal     | 19 (17.7)      |
| WLE and lateral intercostal artery perforator | 1 (0.9) |
| **Margins, mm**         |                |
| Clear margins ≥ 1       | 107 (100)      |
| Clear margins < 1       | 0 (0)          |
| **Node positive breakdown** |            |
| pN0                     | 94 (87.9)      |
| pN1, 1-3                | 13 (12.1)      |
| pN2, 4-9                | 0 (0)          |
| pN3, ≥ 10               | 0 (0)          |

**NOTE.** Data presented as No. (%) unless otherwise indicated. Abbreviations: DCIS, ductal carcinoma in situ; DUCT, ductal carcinoma; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HG, high grade; IDC, invasive ductal carcinoma; IG, intermediate grade; LG, low grade; NST, no special type; PR, progesterone receptor; SD, standard deviation; Tis, tumor in situ; TN, tumor nodes; WLE, wide local excision.

**COVID-19 and IORT Procedure**

The first confirmed case of COVID-19 in South Africa was reported on March 1, 2020, with a complete nationwide lockdown implemented on March 26, 2020. Five patients were treated between December 2019 and May 2020. No alterations to the TARGIT-IORT protocol were undertaken during this period. However, before surgery, patients suspected of contracting COVID-19 had to test negative to limit exposure to clinical staff.

**DISCUSSION**

In recent history, breast cancer mortality rates among developed countries have dropped, with the United States
decades, with multiple studies, including outcome-based studies, detailing its efficacy and noninferior results as compared with EBRT for early-stage breast cancer.10,14-21 IORT as a single fraction immediately after surgery (partial mastectomy) for early-stage small breast cancers, categorized as accelerated partial breast irradiation, has shown to produce positive cosmetic results with a single fraction of in situ RT delivered intraoperatively.22 More than 90% of recurrences of breast cancer occur at or near the tumor bed; hence, a targeted dose of radiation near the operation site should intuitively reduce the recurrence rate.20,23,24 Studies have revealed low local recurrence rates in standard-risk patients who received TARGIT-IORT rather than EBRT.3,17,21 The current study showed a 1.9% (two of 107) recurrence rate. In both of these cases, the patients had high grade (HG) and DCIS characteristics, suggesting that the cancer growth pattern type with HG paired with DCIS is not managed adequately with IORT and that EBRT should be offered instead. Additional studies with a longer follow-up should be undertaken to ascertain the causes and mechanisms associated with HG-DCIS recurrence rates. Although patients presenting with HG-DCIS were not included in the TARGIT-A trial, preliminary research provided evidence that TARGIT is a viable option for patients with DCIS because a low risk of additional therapy (7.3%) and a local recurrence rate of only 4.3% were reported.25

The Intraoperative Radiotherapy With Electrons (ELIOT) trials assessed the frequency and grade of RT–induced pulmonary fibrosis, comparing patients receiving intraoperative electron radiation therapy (IOERT) with those receiving EBRT; the results showed that 4% of the ELIOT arm versus 46% of the EBRT arm developed pulmonary fibrosis, with a higher risk-adjusted recurrence rate in the EBRT arm.14 Although this study provides compelling evidence, notable differences from contemporary IORT studies included the use of IOERT equipment and the visual assessment used for the evaluation of fibrosis.

A recent retrospective study of 127 female patients from 2009 to 2016 characterized patients treated exclusively or with TARGIT-IORT (Zeiss Intrabeam) and detailed demographics, treatment outcomes, complication rates and the feasibility of IORT as a substitute for salvage mastectomy.14 Limitations of the study included the use of a cohort restricted to a single institution with a short follow-up time (4 years) as compared with the minimum 5 years recommended.

The TARGIT-A randomized trial, the largest noninferiority trial with 33 centers in 11 countries, tested the risk-adjusted RT of breast carcinomas between TARGIT-IORT and EBRT while reporting local occurrence rates and overall survival.17 The study consisted of 3,451 patients (1,721 patients randomly assigned to a TARGIT-A group and 1,730 randomly assigned to an EBRT group), and it reported noninferior 5-year risk rates for local recurrence in conserved breast treatment of TARGIT-IORT versus EBRT and lower overall mortality for TARGIT-IORT (3.9% [95% CI. 2.7% to 5.8%]) compared with EBRT (5.3% [95% CI. 3.9% to 7.3%]).26 The study concluded that TARGIT-IORT was noninferior to EBRT and was a viable alternative for patients meeting the criteria, laying a scientific foundation for other efficacy trials comparing traditional cancer therapies.17 These findings were reaffirmed by the updated study and recommended TARGIT-IORT for breast carcinomas in patients ≥ 45 years of age with hormone-sensitive invasive ductal carcinoma up to 3.5 cm in size.27

### TABLE 2. Patient Reasons for Treatment, Additional Treatment, and Oncotype Tests

| Characteristic                                    | No. (%) |
|--------------------------------------------------|---------|
| Primary reason for choosing IORT                  |         |
| Age                                               | 11 (10.3) |
| Age, choice                                       | 3 (2.8) |
| Choice                                            | 43 (40.2) |
| Choice/distance                                   | 3 (2.8) |
| Distance                                          | 47 (43.9) |
| Additional treatment*                             |         |
| Endocrine                                         | 75 (70.1) |
| Not recorded                                      | 11 (10.3) |
| EBRT                                              | 5 (4.7) |
| Refused treatment                                 | 4 (3.7) |
| Chemotherapy                                      | 4 (3.7) |
| EBRT plus chemotherapy                            | 4 (3.7) |
| EBRT plus endocrine                               | 3 (2.8) |
| EBRT plus chemotherapy plus endocrine             | 1 (0.9) |
| Complications                                     |         |
| No complications                                  | 99 (92.5) |
| Hematoma                                          | 4 (3.7) |
| Fat necrosis plus skin erythema                   | 1 (0.9) |
| Skin erythema                                     | 1 (0.9) |
| Fat necrosis                                      | 1 (0.9) |
| Cellulitis                                        | 1 (0.9) |
| Recurrence                                        |         |
| No recurrence                                     | 105 (98.1) |
| Recurrence reoccurred                             | 2 (1.9) |

Abbreviations: EBRT, external-beam radiation therapy; IORT, intraoperative radiation therapy.

*Data omissions due to info not recorded or lost.

recording a 39% decreased mortality rate in breast cancer from 1989 to 2015.11 Conversely, a greater rise in the incidence of breast cancer was reported in developing countries (883,000) than in developed countries (794,000) in 2018.12

IORT is a combined modality therapy used to treat breast cancer by administering radiation directly to the tumor bed after surgery.13 IORT has gained popularity in the past two decades, with multiple studies, including outcome-based studies, detailing its efficacy and noninferior results as compared with EBRT for early-stage breast cancer.10,14-21 These findings were reaffirmed by the updated study and recommended TARGIT-IORT for breast carcinomas in patients ≥ 45 years of age with hormone-sensitive invasive ductal carcinoma up to 3.5 cm in size.27

Ramdas et al
Treatment with the Intrabeam system has been shown to be safe and effective\textsuperscript{2,21,27,28,33}; however, it has been reported that the system requires improvement in the accuracy of the delivered dose.\textsuperscript{29-31} The calibration method, which was established before the start of the TARGIT-A trial (before the year 2000), has been maintained to ensure consistency of the delivered prescription dose, even though newer dosimetry protocols for photons in the kilovoltage energy range have been developed.\textsuperscript{30,32,33}

Patients presenting at this study site displayed unique demographic characteristics and traveled long distances from African countries. Implementation rates of TARGIT-IORT therapies among clinicians in South Africa are low because of a lack of awareness, limited TARGIT-IORT expertise, and the complete absence of other facilities in Africa. These low adoption rates are mirrored by local medical aid funds, which results in most patients funding treatment modalities out of pocket. These factors, driven by the low socioeconomic status of the Southern African region, together with logistics, treatment funding, stigmatization of cancer, and other nonmedical-related taboos, adversely affect treatment adherence.

Because of low medical aid acceptance rates, the majority of patients (> 90%) paid for their treatment, which consisted of surgical, hospital, oncology, technical, and professional fees, using their own resources, which resulted in TARGIT-IORT/IORT being available for the wealthy only. Post-treatment follow-up has yet to record a single case of post-decision dissonance related to IORT/TARGIT-IORT, and most patients recommended the procedure to peers.

A low complication rate of 2.8% (three of 107) was noted, and this compared well with that reported by the TARGIT-A trial of 3.3% when using a similar definition of complication rate.\textsuperscript{45} Four patients experienced hematomas, each requiring a single guided aspiration, and there was no subsequent accumulation of fluid. One patient experienced fat necrosis, but this softened up gradually over 1 year. One patient reported skin erythema, which was treated and resolved with steroid cream. One patient had both skin erythema and fat necrosis; the former was treated with steroid cream and the latter soften gradually over 1 year. The fourth patient reported cellulitis that could not be linked definitively to IORT exposure.

The outbreak of COVID-19 adversely affected the South African health sector through the enforcement of extreme procedural changes specifically in oncologic centers, such as deep cleaning in between patient treatments, social distancing measures, 14-day quarantine rules for those testing positive for COVID-19, and timed slots that reduced the number of radiation treatments per day. Recent discussions within the radiation oncology community have highlighted the challenges affecting patient treatment, such as the patient’s frailty because of advanced disease, colocation with other patients in waiting areas, the specialized staff skill set being negatively affected, interruptions in treatments, and immune-compromised patients and palliative treatments being deprioritized.\textsuperscript{34} These challenges pose notable problems for patients requiring RT, such as the need to present numerous times at hospital treatment centers over a 6-week period. In particular, those meeting the TARGIT-IORT criteria are both elderly and immune compromised, which are key risk factors associated with the disease.\textsuperscript{35} Since December 2019, patients have become more amenable to IORT, because of single treatment therapy in surgery, minimized total hospital contact, and reduced risk of poor treatment adherence.

To the best of our knowledge, before and during the study period, no other research center in Africa was able to administer TARGIT-IORT. This was determined by a comprehensive literature review, media search, verification with major manufacturers such as Carl Zeiss, international IORT conference review, and confirmation with the TARGIT-A trial team in the United Kingdom.\textsuperscript{31}

Thirteen patients received EBRT after IORT treatment, either exclusively or in combination with endocrine therapy and/or chemotherapy. Three patients who received preoperative chemotherapy were meant to continue exclusively with EBRT but opted for IORT in combination with EBRT to reduce treatment times because they lived in rural Africa, travel was a problem, and extending treatment time was not an option. Ten patients had upstage of histology, including positive lymph nodes or human epidermal growth factor receptor 2-positive and higher oncotypes, which migrated them out of the TARGIT-A recommended guidelines, hence, they required EBRT.

As an estimate, more than 60% patients who presented at the study site with histologies similar to the prospective cohort before inception of TARGIT-IORT elected to have BCS. All treatment options, which included mastectomy and BCS, were presented to patients, but the majority elected breast conservation.

TARGIT-IORT has been proven to be noninferior to traditional EBRT treatments, and subsequent research is underway to further hone its applicability, protocols, and benefits.\textsuperscript{17,26,27} Simultaneously, it is predicted that the number of new cancer cases will increase, with those in the United States projected to increase to 2.3 million (a 45% increase) by 2030.\textsuperscript{35} Factors negatively affecting newly diagnosed patients receiving adequate cancer care include a nonuniform oncology practice location, a shortage of oncologists, and lack of access to quality care.\textsuperscript{35} In this study, a critical indication for patients opting for IORT/TARGIT-IORT was distance (43.9%), although the actual travel distance from home to the radiation center was not recorded because multiple factors play a role in the concept of distance in the African environment. Patients from other sub-Saharan countries have limited access to radiation machines; they form a geographically diverse patient base...
with many from nonurban districts forced to travel long distances to attend radiation centers; and those in poorer socioeconomic areas lacking a regular domicile address have the added burden of transport logistics requiring various and multiple public transport services.\textsuperscript{13,36} Patients who chose TARGIT-IORT can expect to travel significantly fewer kilometers related to RT and contribute to lower carbon dioxide emissions which was reported for patients, treated in the UK, forming part of TARGIT-A trial measuring less distance traveled for treatment as compared with those undergoing EBRT.\textsuperscript{36} This retrospective cohort study took place within a 5-year period, which is insufficient time to draw meaningful conclusions related to local recurrence related and time to systemic progression; hence, additional follow-up is required. No TARGIT-IORT recurrences were recorded in this study; however, two IORT recurrences (DCIS group) were noted.

TARGIT-IORT can be a tantalizing option for patients meeting the criteria who are reluctant to travel long distances, would like to avoid numerous trips to medical facilities, and are averse to the frequent cycles of EBRT. However, patients in the elderly subgroup (\textgreater{} 65 years) have reported difficulty in securing daily transport to and from oncology treatment centers because of reliance on family members, lack of adequate public transport, and lack of disposable income for private hire. Follow-on studies should investigate the long-term follow-up of the TARGIT-IORT patient group, potentially comparing this cohort with a cohort composed of EBRT patients, comparing factors such as complication rate, quality of life, and patient treatment preferences (mastectomy, etc.).

This retrospective study of IORT performed in Africa confirms its viability, with low complication rates and no detrimental effects on breast conservation, resulting in positive acceptance and the potential to reduce Oncology Center patient loads caused by the COVID-19 pandemic. Limitations of the study include the use of only short-term data on local recurrence. Health and socioeconomic value models must still be investigated in the African setting.

**AFFILIATIONS**

1. Breast Care Unit, Netcare Milpark Hospital, Johannesburg, South Africa
2. Netcare Medical Physics CoE, Netcare Limited, Sandton, South Africa

**CORRESPONDING AUTHOR**

Yastira Ramdas, MBChB, DCH, MMed, Breast Care Unit, Netcare Milpark, 9 Guild Rd, Parktown, Johannesburg, South Africa, 2000; e-mail: yastiraramdss@gmail.com.

**PRIOR PRESENTATION**

Presented at the 54th ASCO Annual Meeting, Chicago, IL, June 1-5, 2018.

**AUTHOR CONTRIBUTIONS**

Conception and design: All authors
Administrative support: Yastira Ramdas, Carol-Ann Benn
Provision of study material or patients: Carol-Ann Benn
Collection and assembly of data: Yastira Ramdas, Michelle van Heerden
Data analysis and interpretation: Yastira Ramdas, Michelle van Heerden
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors

**REFERENCES**

1. National Cancer Institute: Breast cancer - patient version. https://www.cancer.gov/types/breast
2. Silva RM, Pinheiro CPO, Bezerra IC, et al: Mastectomy and the meaning attributed by patients to delay in early diagnosis of breast cancer. Asian Pac J Cancer Prev 19:2083-2088, 2018
3. Vaidya JS, Tobias JS, Baum M, et al: Intraoperative radiotherapy for breast cancer. Lancet Oncol 5:165-173, 2004
4. Harris EER, Small W Jr: Intraoperative radiotherapy for breast cancer. Front Oncol 7:317, 2017
5. Ligher J, Phillips M, Hochman S, et al: Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission. Clin Infect Dis 71:896-897, 2020
6. Wu YC, Chen CS, Chan YJ: The outbreak of COVID-19: An overview. J Chin Med Assoc 83:217-220, 2020
7. Kutikov A, Weinberg DS, Edelman MJ, et al: A war on two fronts: Cancer care in the time of COVID-19. Ann Intern Med 172:756-758, 2020
8. Burki TK: Cancer guidelines during the COVID-19 pandemic. Lancet Oncol 21:629-630, 2020
9. Pharmas-ethics: www.pharma-ethics.co.za.
10. Correa C, Harris EE, Leonard MC, et al: Accelerated partial breast irradiation: Executive summary for the update of an ASTRO evidence-based consensus statement. Pract Radiat Oncol 7:73-79, 2017
11. DeSantis CE, Ma J, Goding Sauer A, et al: Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin 67:439-448, 2017
12. WHO: Global Cancer Observatory: Malaysia Cancer Stat 593:1-2, 2019
13. Hoekstra HJ, Sindelar WF, Kinsella TJ, et al: History, preliminary results, complications, and future prospects of intraoperative radiotherapy. J Surg Oncol 36:175-182, 1987
14. Rana S, Naik A, Pillai S, et al: Outcomes of intraoperative radiotherapy for early-stage breast cancer: Experience from a multidisciplinary breast oncology program. Am J Surg 219:655-659, 2000
15. Vaidya JS, Tobias JS, Baum M, et al: TARGETed intraoperative radiotherapy (TARGIT): An innovative approach to partial-breast irradiation. Semin Radiat Oncol 15:84-91, 2005
16. Luini A, Orecchia R, Gatti G, et al: The pilot trial on intraoperative radiotherapy with electrons (ELIOT): Update on the results. Breast Cancer Res Treat 93:55-59, 2005
17. Vaidya JS, Wenz F, Bulsara M, et al: An international randomised controlled trial to compare TARGETed Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technol Assess 20:1-188, 2016
18. Calvo FA, Meirino RM, Orecchia R: Intraoperative radiation therapy first part. Rationale and techniques. Crit Rev Oncol Hematol 59:106-115, 2006
19. Ng J, Khani J, Zhuo R, et al: Safety, feasibility, and short-term clinical outcomes for locally recurrent breast cancer patients treated with a second breast-conserving treatment including intraoperative radiation therapy. Int J Radiat Oncol 96:E32-E33, 2016
20. Esposito E, Douek M: Update on intraoperative radiotherapy: New challenges and issues. Ecamermedicalsience 12:793, 2018
21. Vaidya JS, Baum M, Tobias JS, et al: Long-term results of targeted intraoperative radiotherapy (Targit) boost during breast-conserving surgery. Int J Radiat Oncol Biol Phys 81:1091-1097, 2011
22. Ollila DW, Klauber-DeMore N, Tesche LJ, et al: Feasibility of breast preserving therapy with single fraction in situ radiotherapy delivered intraoperatively. Ann Surg Oncol 14:660-669, 2007
23. Drew PJ, Tumblow LW, Kerin MJ, et al: Multicentricity and recurrence of breast cancer. Lancet 349:208-209, 1997
24. Vaidya JS, Vyas JJ, Chinoy RF, et al: Multicentricity of breast cancer: Whole-organ analysis and clinical implications. Br J Cancer 74:820-824, 1996
25. Banks A, Coronado G, Zimmerman R, et al: Breast conserving surgery with targeted intraoperative radiotherapy for the management of ductal carcinoma in situ. J Surg Oncol 119:409-420, 2019
26. Vaidya JS, Joseph DJ, Tobias JS, et al: Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): An international, prospective, randomised, non-inferiority phase 3 trial. Lancet 376:91-102, 2010 [Erratum: Lancet 376:90, 2010]
27. Vaidya JS, Wenz F, Bulsara M, et al: Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-Year results for local control and overall survival from the TARGIT-A randomised trial. Lancet 383:603-613, 2014 [Erratum: Lancet 383:602, 2014]
28. Sedlmayer F, Reitsamer R, Fuss C, et al: Boost IORT in breast cancer: Body of evidence. Int J Breast Cancer 2014:472516, 2014
29. Watson PGF, Popovic M, Seuntjens J: Determination of absorbed dose to water from a miniature kilovoltage x-ray source using a parallel-plate ionization chamber. Phys Med Biol 63:015016, 2017
30. Watson PGF, Bekerat H, Papaconstadopoulos P, et al: An investigation into the INTRABEAM miniature x-ray source dosimetry using ionization chamber and radiochromic film measurements. Med Phys 45:4274-4286, 2018
31. Ebert MA, Caruthers B: Dosimetric characteristics of a low-kV intra-operative x-ray source: Implications for use in a clinical trial for treatment of low-risk breast cancer. Med Phys 30:2424-2431, 2003
32. Ma CM, Coffey CW, DeWerd LA, et al: AAPM protocol for 40-300 kV x-ray beam dosimetry in radiotherapy and radiobiology. Med Phys 28:868-893, 2001
33. IAEA: IAEA TRS 398: Absorbed dose determination in external beam radiotherapy: An international code of practice for dosimetry based on standards of absorbed dose to water. http://www-na.wi.iaea.org/naah/DMRP/documents/CoP_V12_2006-06-05.pdf
34. Simcock R, Thomas TV, Estes C, et al: COVID-19: Global radiation oncology’s targeted response for pandemic preparedness. Clin Transl Radiat Oncol 22:55-68, 2020
35. Kirkwood MK, Hanley A, Bruijnooge SS, et al: The state of cancer care in America, 2017: A report by the American Society of Clinical Oncology. J Oncol Pract 14:12-20, 2018
36. Coombs NJ, Coombs JM, Vaidya UJ, et al: Environmental and social benefits of the targeted intraoperative radiotherapy for breast cancer: Data from UK TARGIT-A trial centres and two UK NHS hospitals offering TARGIT IORT. BMJ Open 6:e010703, 2016
37. Giuliano AE, Connolly JL, Edge SB, et al: Breast cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67:290-303, 2017